Payment overview · 2025
General Payments
$1,338.81
66 reported records · 13 companies
Healthcare provider profile · identity verified
Nancy Alkire, MD
Allopathic & Osteopathic Physicians|Family Medicine · CIRCLEVILLE, OH · NPI 1710924659
Verified facts
What the public records show
CMS Open Payments records show Nancy Alkire, MD received $1,338.81 in general payments during 2025 across 66 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $448.44 | 33.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $172.77 | 12.9% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $159.68 | 11.9% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $144.12 | 10.8% | 14 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $123.60 | 9.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $70.65 | 5.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $46.31 | 3.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.78 | 3.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.96 | 3.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.03 | 2.2% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.33 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.40 | 1.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.74 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,338.81 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $365.44 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $231.42 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $210.62 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $144.12 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $130.55 | 9 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $123.60 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $80.44 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $79.24 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $70.65 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $46.31 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.96 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.03 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.03 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.83 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.38 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 384 | 100 |
| Omeprazole | Omeprazole | 358 | 66 |
| Lisinopril | Lisinopril | 344 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 77 |
| Metformin Hcl | Metformin Hcl | 293 | 73 |
| Gabapentin | Gabapentin | 261 | 71 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 227 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 203 | 53 |
| Losartan Potassium | Losartan Potassium | 202 | 48 |
| Montelukast Sodium | Montelukast Sodium | 198 | 51 |
| Furosemide | Furosemide | 194 | 60 |
| Trazodone Hcl | Trazodone Hcl | 172 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 42 |
| Tramadol Hcl | Tramadol Hcl | 157 | 38 |
| Simvastatin | Simvastatin | 150 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 37 |
| Prednisone | Prednisone | 141 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 40 |
| Azithromycin | Azithromycin | 134 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 36 |
| Oxycodone Hcl | Oxycodone Hcl | 130 | 37 |
| Eliquis | Apixaban | 124 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 23 |
| Lorazepam | Lorazepam | 119 | 44 |
| Glimepiride | Glimepiride | 118 | 20 |
| Ozempic | Semaglutide | 118 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 29 |
| Alprazolam | Alprazolam | 109 | 18 |
| Carvedilol | Carvedilol | 104 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 23 |
| Donepezil Hcl | Donepezil Hcl | 86 | 17 |
| Finasteride | Finasteride | 82 | 18 |
| Spironolactone | Spironolactone | 79 | 25 |
| Famotidine | Famotidine | 77 | 19 |
| Atenolol | Atenolol | 75 | 16 |
| Allopurinol | Allopurinol | 73 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 18 |
| Cephalexin | Cephalexin | 68 | 46 |
| Propranolol Hcl | Propranolol Hcl | 67 | 13 |
| Mirtazapine | Mirtazapine | 59 | 18 |
| Memantine Hcl | Memantine Hcl | 57 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 17 |
| Clonidine Hcl | Clonidine Hcl | 55 | 14 |
| Methylprednisolone | Methylprednisolone | 49 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 11 |
| Sertraline Hcl | Sertraline Hcl | 46 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 11 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 31 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 40 | 14 |
| Methadone Hcl | Methadone Hcl | 40 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 36 | 12 |
| Potassium Chloride | Potassium Chloride | 35 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 13 |
| Loperamide | Loperamide Hcl | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 19 |
| Jardiance | Empagliflozin | 33 | suppressed |
| Estradiol | Estradiol | 32 | 11 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 25 |
| Meclizine Hcl | Meclizine Hcl | 31 | 11 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Fluconazole | Fluconazole | 26 | 19 |
| Naproxen | Naproxen | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | 12 |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 18 |
| Nystatin | Nystatin | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 11 |
| Meloxicam | Meloxicam | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Trueplus Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Nifedipine | Nifedipine | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Lorazepam Intensol | Lorazepam | 12 | 12 |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Torsemide | Torsemide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 11 | suppressed |
| Thiothixene | Thiothixene | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,338.81 · 66 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CREON, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, JOURNAVX, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, VRAYLAR, WATCHMAN Access System, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error